A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse
A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse
复制标题
20 mg 法莫替丁 nocte 与 150 mg 雷尼替丁 nocte 预防十二指肠溃疡复发的对照研究
DOI：
10.1111/j.1365-2036.1991.tb00019.x
复制
发表时间：
1991
影响因子：
7.6
通讯作者：
A. Calacro
中科院分区：
文献类型：
--
作者：
G. Porro;M. Lazzaroni;L. Barbara;R. Corinaldesi;A. Blasi;A. Mangiameli;L. Capurso;M. Koch;R. Cheli;E. Bovero;R. Franchis;M. Guslandi;A. Francavilla;M. Ingrosso;G. Gasbarrini;G. Zoli;G. Mazzacca;F. Sabbatini;R. Naccarato;F. Mario;P. Paoluzi;M. Agnello;L. Scuro;G. Cavallini;C. Surrenti;A. Calacro
一项在13个中心进行的为期24周的双盲随机研究比较了20mg法莫替丁和150mg雷尼替丁预防十二指肠溃疡复发的疗效和安全性。所有参与者都成功地用40毫克法莫替丁治疗急性十二指肠溃疡。患者在基线和24周时接受内窥镜检查，除非症状需要早期检查：在入组的208名患者中，86名接受法莫替丁治疗的患者和84名接受雷尼替丁治疗的患者符合所有方案标准，并被认为是可评估的。
A 24‐week, double‐blind, randomized study at 13 centres compared the efficacy and safety of 20 mg famotidine nocte and 150 mg ranitidine h.s. for the prevention of duodenal ulcer recurrence. All participants had been successfully treated for an acute duodenal ulcer with 40 mg famotidine nocte. Patients were endoscoped at baseline and at 24 weeks, unless symptoms warranted earlier examination: of the 208 patients enrolled, 86 who received famotidine and 84 who received ranitidine met all protocol criteria and were considered evaluable.